Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial.

Haynes R, Valdes-Marquez E, Hopewell JC, Chen F, Li J, Parish S, Landray MJ, Armitage J; HPS2-THRIVE Collaborative Group; HPS2-THRIVE Writing Committee members; HPS2-THRIVE Steering Committee members.

Clin Ther. 2019 Sep;41(9):1767-1777. doi: 10.1016/j.clinthera.2019.06.012. Epub 2019 Aug 22.

PMID:
31447131
2.

Relative effects of LDL-C on ischemic stroke and coronary disease: A Mendelian randomization study.

Valdes-Marquez E, Parish S, Clarke R, Stari T, Worrall BB; METASTROKE Consortium of the ISGC,, Hopewell JC.

Neurology. 2019 Mar 12;92(11):e1176-e1187. doi: 10.1212/WNL.0000000000007091. Epub 2019 Feb 20.

3.

Plasma cytokines and risk of coronary heart disease in the PROCARDIS study.

Clarke R, Valdes-Marquez E, Hill M, Gordon J, Farrall M, Hamsten A, Watkins H, Hopewell JC.

Open Heart. 2018 Apr 25;5(1):e000807. doi: 10.1136/openhrt-2018-000807. eCollection 2018.

4.

Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study.

Parish S, Hopewell JC, Hill MR, Marcovina S, Valdes-Marquez E, Haynes R, Offer A, Pedersen TR, Baigent C, Collins R, Landray M, Armitage J; HPS2-THRIVE Collaborative Group.

Circ Genom Precis Med. 2018 Feb;11(2):e001696. doi: 10.1161/CIRCGEN.117.001696.

5.

Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke.

Hopewell JC, Malik R, Valdés-Márquez E, Worrall BB, Collins R; METASTROKE Collaboration of the ISGC.

Eur Heart J. 2018 Feb 1;39(5):354-359. doi: 10.1093/eurheartj/ehx373.

6.

Mendelian randomization with fine-mapped genetic data: Choosing from large numbers of correlated instrumental variables.

Burgess S, Zuber V, Valdes-Marquez E, Sun BB, Hopewell JC.

Genet Epidemiol. 2017 Dec;41(8):714-725. doi: 10.1002/gepi.22077. Epub 2017 Sep 25.

7.

Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics.

REVEAL Collaborative Group, Bowman L, Chen F, Sammons E, Hopewell JC, Wallendszus K, Stevens W, Valdes- Marquez E, Wiviott S, Cannon CP, Braunwald E, Collins R, Landray MJ.

Am Heart J. 2017 May;187:182-190. doi: 10.1016/j.ahj.2017.02.021. Epub 2017 Feb 21.

8.

Genetic loci on chromosome 5 are associated with circulating levels of interleukin-5 and eosinophil count in a European population with high risk for cardiovascular disease.

McLeod O, Silveira A, Valdes-Marquez E, Björkbacka H, Almgren P, Gertow K, Gådin JR, Bäcklund A, Sennblad B, Baldassarre D, Veglia F, Humphries SE, Tremoli E, de Faire U, Nilsson J, Melander O, Hopewell JC, Clarke R, Björck HM, Hamsten A, Öhrvik J, Strawbridge RJ; IMPROVE Study Group.

Cytokine. 2016 May;81:1-9. doi: 10.1016/j.cyto.2016.01.007. Epub 2016 Jan 25.

9.

Use of secondary preventive medications in patients with atherosclerotic disease in urban China: a cross-sectional study of 16, 860 patients.

Li J, Chen YP, Li X, Armitage J, Feng F, Liu JM, Gao Y, Zhang HB, Zhang D, Hundei WB, Chen ZM, Chen F, Hopewell JC, Valdes-Marquez E, Landray M, Jiang LX; HPS2-THRIVE Collaborative Group.

Chin Med J (Engl). 2012 Dec;125(24):4361-7.

PMID:
23253702
10.

A practical comparison of blinded methods for sample size reviews in survival data clinical trials.

Todd S, Valdés-Márquez E, West J.

Pharm Stat. 2012 Mar-Apr;11(2):141-8. doi: 10.1002/pst.516. Epub 2012 Feb 15.

PMID:
22337635
11.

Designing a seamless phase II/III clinical trial using early outcomes for treatment selection: an application in multiple sclerosis.

Friede T, Parsons N, Stallard N, Todd S, Valdes Marquez E, Chataway J, Nicholas R.

Stat Med. 2011 Jun 15;30(13):1528-40. doi: 10.1002/sim.4202. Epub 2011 Feb 22.

PMID:
21341301
12.

A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis.

Chataway J, Nicholas R, Todd S, Miller DH, Parsons N, Valdés-Márquez E, Stallard N, Friede T.

Mult Scler. 2011 Jan;17(1):81-8. doi: 10.1177/1352458510382129. Epub 2010 Aug 26.

PMID:
20798135
13.

Using historical lesion volume data in the design of a new phase II clinical trial in acute stroke.

Whitehead J, Bolland K, Valdès-Márquez E, Lihic A, Ali M, Lees K; Virtual International Stroke Trials Archive Collaborators.

Stroke. 2009 Apr;40(4):1347-52. doi: 10.1161/STROKEAHA.108.531442. Epub 2009 Feb 19.

PMID:
19228847
14.

A simple two-stage design for quantitative responses with application to a study in diabetic neuropathic pain.

Whitehead J, Valdés-Márquez E, Lissmats A.

Pharm Stat. 2009 Apr-Jun;8(2):125-35. doi: 10.1002/pst.341.

PMID:
18642403
15.

Bayesian sample size for exploratory clinical trials incorporating historical data.

Whitehead J, Valdés-Márquez E, Johnson P, Graham G.

Stat Med. 2008 Jun 15;27(13):2307-27.

PMID:
18069728

Supplemental Content

Loading ...
Support Center